Neurotrope and Metuchen Pharmaceuticals announced the companies have merged in an all-stock deal to form Petros Pharmaceuticals, which is focused on men’s health conditions.
Boston Scientific announced a definitive agreement to acquire Augmenix Inc., a privately held company that has developed and commercialized the SpaceOAR System, a therapy used to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy.
